Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941661 | 0.90 | MMP1 (0.50) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL942388 | 0.90 | MMP1 (0.50) | MMP1FPR2PROKR1KCNH2OPRK1 | |
| SCHEMBL940600 | 0.85 | MMP1 (0.57) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL942470 | 0.84 | MMP1 (0.49) | MMP1FPR2PROKR1KCNH2OPRK1 | |
| SCHEMBL943749 | 0.83 | MMP1 (0.56) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL941513 | 0.83 | FPR2 (0.50) | MMP1FPR2PROKR1KCNH2LMNA | |
| SCHEMBL941398 | 0.81 | MMP1 (0.54) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL942540 | 0.80 | MMP1 (0.58) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL941286 | 0.80 | MMP1 (0.49) | MMP1FPR2PROKR1LMNATP53 | |
| SCHEMBL941419 | 0.79 | MMP1 (0.49) | MMP1FPR2PROKR1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | claimed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP1 10/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP1 10/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP1 17/4885FPR2 1510/4885PROKR1 2106/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | MMP1 3021/4885FPR2 4109/4885PROKR1 1008/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP1 14/4885FPR2 1887/4885PROKR1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.